Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?,Hepatology International

当前位置： X-MOL 学术 › Hepatol. Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?
Hepatology International ( IF 5.9 ) Pub Date : 2023-05-02 , DOI: 10.1007/s12072-023-10535-8
Renguo Guan _{1,

2,

3} , Jie Mei _{1,

2,

3} , Wenping Lin _{1,

2,

3} , Min Deng _{1,

2,

3} , Shaohua Li _{1,

2,

3} , Rongping Guo _{1,

2,

3}

Affiliation

Background

The level of C‑reactive protein (CRP) and alpha‑fetoprotein (AFP) in immunotherapy (CRAFITY) score was associated with the prognosis of hepatocellular carcinoma (HCC) patients treated with immunotherapy. Based on the CRAFITY score, this study aimed to investigate the efficacy and safety of locoregional-immunotherapy for treating HCC patients.

Methods

HCC patients who received locoregional-immunotherapy were consecutively recruited at Sun Yat-sen University Cancer Center in 2019. CRAFITY 0 score was defined as the AFP level below 100 ng/ml and a CRP level of less than 1 mg/dl, CRAFITY 1 score was defined as the AFP level of at least 100 ng/ml or the CRP level of at least 1 mg/dl, and CRAFITY 2 score was defined as both the AFP level over 100 ng/ml and the CRP level of more than 1 mg/dl. The primary outcomes were progression-free survival (PFS) and overall survival (OS). The second outcomes were tumor response rate and treatment-related adverse events (AEs).

Results

The median PFS for HCC patients with the CRAFITY 0 score was not estimable. The PFS was 11.0 months [95% confidence interval (CI) 7.2–14.9] and 6.0 months (95% CI 4.2–7.8) for patients with CRAFITY 1 and 2 scores, respectively, with a significant difference between the two groups (p < 0.001). HCC patients with CRAFITY 0, 1, and 2 scores had 3 years OS rates of 63.8%, 60.8%, and 32.1%, respectively, with statistical differences among the three groups (p < 0.001). Patients with the CRAFITY 2 score were more likely to experience fever than those with other scores (p < 0.05). A greater CRAFITY score was correlated with a higher incidence of grade 3 and above liver injury (p < 0.01).

Conclusions

The CRAFITY score is a superior predictor of prognosis and treatment-related AEs in HCC patients treated with locoregional-immunotherapy.

中文翻译：

CRAFITY 评分是否是接受局部免疫治疗的肝细胞癌患者预后和不良事件的较好预测指标？

背景

免疫治疗（CRAFITY）评分中C反应蛋白（CRP）和甲胎蛋白（AFP）的水平与接受免疫治疗的肝细胞癌（HCC）患者的预后相关。本研究基于 CRAFITY 评分，旨在探讨局部免疫治疗治疗 HCC 患者的有效性和安全性。

方法

2019年中山大学肿瘤防治中心连续招募接受局部免疫治疗的HCC患者。CRAFITY 0分定义为AFP水平低于100 ng/ml且CRP水平低于1 mg/dl，CRAFITY 1分CRAFITY 2 评分定义为 AFP 水平至少 100 ng/ml 或 CRP 水平至少 1 mg/dl，CRAFITY 2 评分定义为 AFP 水平超过 100 ng/ml 且 CRP 水平超过 1 mg /dl。主要结局是无进展生存期（PFS）和总生存期（OS）。第二个结果是肿瘤缓解率和治疗相关不良事件（AE）。

结果

CRAFITY 0 评分的 HCC 患者的中位 PFS 无法估计。 CRAFITY 1 和 2 评分患者的 PFS 分别为 11.0 个月 [95% 置信区间 (CI) 7.2–14.9] 和 6.0 个月 (95% CI 4.2–7.8)，两组之间存在显着差异 ( p < 0.001）。 CRAFITY 0、1、2 分的 HCC 患者的 3 年 OS 率分别为 63.8%、60.8% 和 32.1%，三组之间具有统计学差异（ p < 0.001）。 CRAFITY 2 评分的患者比其他评分的患者更有可能发烧 ( p < 0.05)。 CRAFITY 评分越高，3 级及以上肝损伤的发生率越高（ p < 0.01）。